NCT00698490View on ClinicalTrials.gov

Humoral and Cellular Immune Response of Herpes Simplex (gD) Candidate Vaccines From 2 Different Cell Lines

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

August 31, 1995

Primary Completion Date

January 31, 1997

Study Completion Date

January 31, 1997

Conditions
Prophylaxis Herpes Simplex
Interventions
BIOLOGICAL

Adjuvanted herpes simplex (gD) candidate vaccine GSK 208141

Intramuscular injection, 3 doses, 2 different formulations

BIOLOGICAL

Herpes simplex virus containing gD-Alum

Intramuscular injection, 3 doses

Trial Locations (1)

Unknown

GSK Clinical Trials Call Center, Ghent

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY